(Q35569462)

8 August 2017

1 reference

title

Thalidomide and its derivatives: new promise for multiple myeloma (English)

1 reference

8 August 2017

Thalidomide and Its Derivatives: New Promise for Multiple Myeloma (English)

1 reference

https://api.crossref.org/works/10.1177/107327480301000504

25 March 2024

0 references

1 reference

https://api.crossref.org/works/10.1177/107327480301000504

25 March 2024

author name string

Donna Weber

series ordinal

1

1 reference

8 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14581892

25 March 2024

publication date

1 September 2003

1 reference

full work available at URL

8 August 2017

http://journals.sagepub.com/doi/pdf/10.1177/107327480301000504

1 reference

https://api.crossref.org/works/10.1177/107327480301000504

25 March 2024

1 reference

8 August 2017

10

1 reference

8 August 2017

375-383

1 reference

8 August 2017

5

1 reference

8 August 2017

Cancer statistics, 2003.

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000504

Effective treatment of advanced multiple myeloma refractory to alkylating agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000504

Thalidomide is an inhibitor of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000504

Bone marrow angiogenesis and progression in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000504

Increased bone marrow microvessel density in newly diagnosed multiple myeloma carries a poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000504

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000504

Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000504

Thalidomide: emerging role in cancer medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000504

Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000504

Binding of thalidomide to alpha1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000504

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000504

The role of adhesion receptors in the pathogenesis of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000504

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000504

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000504

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000504

Thalidomide alone or with dexamethasone for previously untreated multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000504

S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000504

Deep venous thrombosis and thalidomide therapy for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000504

Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000504

Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000504

Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the Intergroupe Francophone du Myélome (IFM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000504

Thalidomide and dexamethasone combination for refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000504

Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000504

Thalidomide in the management of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000504

Thalidomide for previously untreated indolent or smoldering multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000504

Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000504

Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000504

Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000504

Impact of complete remission with intensive therapy in patients with responsive multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000504

Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group

21 January 2018

series ordinal

2

1 reference

https://api.crossref.org/works/10.1177/107327480301000504

Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration

25 March 2024

series ordinal

14

1 reference

https://api.crossref.org/works/10.1177/107327480301000504

25 March 2024

17

59

728

Bellamy W.

1999

1 reference

https://api.crossref.org/works/10.1177/107327480301000504

25 March 2024

Identifiers

0 references

1 reference